-
A Diverse Health Care Practice: Videos
When clients are facing challenges with a health care component, they count on Analysis Group’s unique ability to build a diverse team to address every aspect of the question at hand. Drawing on our health care group’s expertise, we provide assistance with matters related to litigation; health economics and outcomes research (HEOR); epidemiology and drug safety; market access, pricing/contracting, and commercial strategy; and public policy assessments.
Hear from Managing Principal and Director, Health Care Practice, Paul Greenberg, about the breadth of our health care work, what distinguishes our practice from others, and the unique value that we provide to clients.
AG Feature
-
-
- For the past 30 years, a research team led by Analysis Group Managing Principal Paul E. Greenberg has been studying the economic burden of US adults with depression.
Paul GreenbergThe Economic Burden of Depression: 30-Year Study - The economics of bringing rare disease drugs to market can be daunting. But sophisticated economic modeling can help drug developers make the best use of the relevant evidence about efficacy and value when it comes to pricing and reimbursement decisions.
James SignorovitchRare Diseases - The use of real-world evidence to augment clinical trials is gaining recognition. By applying rigorous standards for collection and analysis, data from mobile health devices, emails, and even social media can help improve a drug’s prospects.
Patrick LefebvreThe Value of Real-World Evidence in Drug Approval and Marketing Processes - Dossiers that effectively and comprehensively document a drug’s value are critical for pricing, reimbursement, and coverage decisions.
Dave NellesenWhat Are Dossiers? - The rising cost of prescription drugs is leading many recent headlines. However, a narrow focus on increased costs alone fails to capture how innovative therapies may offer patients considerable value relative to existing therapies.
Noam KirsonBalancing Drug Pricing With Value - New systems of advanced Suspicious Order Monitoring (SOM) algorithms are helping manufacturers, distributors, pharmacies, and providers to distinguish between legitimate and illegitimate orders of controlled substances such as prescription opioids.
Crystal Pike and Kenneth WeinsteinUsing Data in Suspicious Order Monitoring of Opioids - Patient-reported outcome (PRO) instruments provide robust assessments of the burden of a disease or the benefits of a treatment. In pharmaceutical approvals, regulatory agencies are increasingly incorporating PROs into clinical assessments.
Eric Wu and Min YangPatient Reported Outcomes - While intellectual property and antitrust litigation involving pharmaceuticals has long been widespread in the US, the recent emergence of biosimilar drugs has raised a number of questions around how this litigation will evolve.
Richard MortimerThe Competitive Landscape for Biosimilars
- For the past 30 years, a research team led by Analysis Group Managing Principal Paul E. Greenberg has been studying the economic burden of US adults with depression.